Ecopia BioSciences Inc.
TSX : EIA

Ecopia BioSciences Inc.

April 11, 2006 16:07 ET

Highlights From Ecopia's Annual General Meeting of Shareholders

MONTREAL, QUEBEC--(CCNMatthews - April 11, 2006) - Ecopia BioSciences Inc. (TSX:EIA) held today its Annual General Meeting of Shareholders at the McGill Faculty Club & Conference Centre in Montreal. Dr. Pierre Falardeau, President and Chief Executive Officer of Ecopia, told shareholders: "During the last year, an important milestone has been achieved as we have successfully progressed from being a preclinical development company to a clinical stage company. This new positioning is of great importance, as it will allow us to move forward in establishing proof of principle in humans for our first clinical candidate, ECO-4601. This advancement further validates the power of our DECIPHER® technology to deliver potential drugs from nature."

One of Ecopia's main objectives in 2005 was to file a Clinical Trial Application for ECO-4601, in order to start a Phase I clinical trial involving the Company's lead anticancer compound. The filing was sent to the Canadian regulatory authorities before year-end 2005 and, in early February 2006, the Therapeutic Products Directorate of Health Canada issued a No Objection Letter, allowing the Company to start its Phase I clinical trial. Treatment of the first patient was initiated on April 5, 2006. Ecopia's intellectual property efforts were also greatly rewarded. Last December, the Company received from the USPTO a Notice of Allowance on the patent application directed to the chemical structure of ECO-4601. The structural novelty of ECO-4601 led Ecopia to develop an analog program, which was another achievement for the Company. This program allowed the synthesis of more than 60 ECO-4601 analogs and a better understanding of the compound's structure-activity relationships.

During the upcoming year, the Company will keep you informed on the progress of its Phase I clinical trial, which should be completed by early 2007. Management also believes that the analog program will allow the selection of a second lead compound and its advancement towards a second regulatory filing.

About Ecopia

Ecopia is finding novel anticancer therapies from soil-dwelling microorganisms that are one of the most prolific sources of drugs. Our current focus is to advance our flagship compound, ECO-4601, through the different stages of clinical trials. ECO-4601 is a novel small molecule that crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class that is the fruit of a very unique drug discovery platform called the DECIPHER® technology. The common shares of Ecopia are listed on the TSX (symbol: EIA).

Additional information about the Company can be obtained from Ecopia's website at www.ecopiabio.com.

Certain statements in this press release that do not relate exclusively to historical facts are forward-looking statements. When used in this press release, the expressions "will", "should be", "believes", "advancement towards" and similar expressions, as they relate to ECO-4601, Ecopia or Ecopia's management are intended to identify forward-looking statements. Forward-looking statements regarding the potential of ECO-4601 to treat brain cancer in humans are based on data from pre-clinical animal studies. The forward-looking statement regarding selection of a second lead compound is based on the current state of the Company's analog program. These statements are only predictions and are therefore subject to risks and uncertainties, which are outside the Company's control. Actual events could differ materially from those projected here and depend on a number of factors, including scientific uncertainties relating to the correlation between preclinical animal data and clinical human data, the ability of the Company to fund future operations, and the impact of general economic conditions. Investors are cautioned against placing undue reliance on forward-looking statements. A more complete discussion of the risks and uncertainties facing the Company appears in the Management's Discussion and Analysis for financial year-end 2005 and the 2005 Annual Information Form, available at www.sedar.com. Except as required by law, Ecopia does not undertake and disclaims any obligation to update or revise its forward-looking statements.

Contact Information